Overview

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis. OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formulation. SORILUX Foam is a foam formulation of calcipotriene. Both medications have been approved by the FDA for treating plaque psoriasis.

Phase:

Phase 4

Details

Lead Sponsor:

Leon Kircik, M.D.

Collaborator:

Stiefel, a GSK Company

Treatments:

Calcipotriene
Calcitriol
Clobetasol